AbClon
AT101(Anti-CD19 Chimeric Antigen Receptor T cell)(AbClon)은 CD19 표적 세포·유전자 치료로, B-cell Non Hodgkin Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: CAR T-cell therapy was not independently associated with improved OS or LFS. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 38% (ClinicalTrials.gov NCT05537766). 차별점: unique protein scaffold linking interleukin-7 (IL-7), an IL-15/IL-15 receptor α (IL-15Rα) complex, and IL-21, gene.
CD19
B-cell Non Hodgkin Lymphoma
Recruiting
bispecific antibodies as salvage therapy after CAR-T failure in relaps
vedotin-containing regimens as bridge to CART:
linker sequences
retroviral vectors to express CD19 (Molm-13-CD19), turning them into potential AML targets
humanized mouse HIV infection model, HCW9206-generated anti-HIV duoCAR T cells suppressed viremia more effect
unique protein scaffold linking interleukin-7 (IL-7), an IL-15/IL-15 receptor α (IL-15Rα) complex, and IL-21, gene
CAR T-cell therapy was not independently associated with improved OS or LFS
Cytokine release syndrome was the most common toxicity, predominantly grade 1-2, while neurotoxicity and hematologic
CD19 CAR T-cell therapy can achieve high
escape while maintaining a tolerable toxicity profile
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
AbClon
AT101(Anti-CD19 Chimeric Antigen Receptor T cell)(AbClon)은 CD19 표적 세포·유전자 치료로, B-cell Non Hodgkin Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: CAR T-cell therapy was not independently associated with improved OS or LFS. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 38% (ClinicalTrials.gov NCT05537766). 차별점: unique protein scaffold linking interleukin-7 (IL-7), an IL-15/IL-15 receptor α (IL-15Rα) complex, and IL-21, gene.
CD19
B-cell Non Hodgkin Lymphoma
Recruiting
bispecific antibodies as salvage therapy after CAR-T failure in relaps
vedotin-containing regimens as bridge to CART:
linker sequences
retroviral vectors to express CD19 (Molm-13-CD19), turning them into potential AML targets
humanized mouse HIV infection model, HCW9206-generated anti-HIV duoCAR T cells suppressed viremia more effect
unique protein scaffold linking interleukin-7 (IL-7), an IL-15/IL-15 receptor α (IL-15Rα) complex, and IL-21, gene
CAR T-cell therapy was not independently associated with improved OS or LFS
Cytokine release syndrome was the most common toxicity, predominantly grade 1-2, while neurotoxicity and hematologic
CD19 CAR T-cell therapy can achieve high
escape while maintaining a tolerable toxicity profile
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.